O	0	5	Phase
O	6	8	II
O	9	19	randomized
O	20	25	study
O	26	28	of
B-intervention	29	40	trastuzumab
I-intervention	41	50	emtansine
O	51	57	versus
B-control	58	69	trastuzumab
I-control	70	74	plus
I-control	75	84	docetaxel
O	85	87	in
O	88	96	patients
O	97	101	with
O	102	107	human
O	108	117	epidermal
O	118	124	growth
O	125	131	factor
O	132	140	receptor
O	141	142	2
O	142	143	-
O	143	151	positive
O	152	162	metastatic
O	163	169	breast
O	170	176	cancer
O	176	177	.

O	178	189	Trastuzumab
O	190	199	emtansine
O	200	201	(
O	201	202	T
O	202	203	-
O	203	206	DM1
O	206	207	)
O	207	208	,
O	209	211	an
O	212	220	antibody
O	220	221	-
O	221	225	drug
O	226	235	conjugate
O	236	244	composed
O	245	247	of
O	248	251	the
O	252	261	cytotoxic
O	262	267	agent
O	268	271	DM1
O	272	282	conjugated
O	283	285	to
O	286	297	trastuzumab
O	298	301	via
O	302	303	a
O	304	310	stable
O	311	320	thioether
O	321	327	linker
O	327	328	,
O	329	332	has
O	333	338	shown
O	339	347	clinical
O	348	356	activity
O	357	359	in
O	360	366	single
O	366	367	-
O	367	370	arm
O	371	378	studies
O	379	388	enrolling
O	389	397	patients
O	398	402	with
O	403	408	human
O	409	418	epidermal
O	419	425	growth
O	426	432	factor
O	433	441	receptor
O	442	443	2
O	444	445	(
O	445	449	HER2
O	449	450	)
O	451	452	-
O	452	460	positive
O	461	471	metastatic
O	472	478	breast
O	479	485	cancer
O	486	487	(
O	487	490	MBC
O	490	491	)
O	492	497	whose
O	498	505	disease
O	506	509	had
O	510	520	progressed
O	521	523	on
O	524	528	HER2
O	528	529	-
O	529	537	targeted
O	538	545	therapy
O	546	548	in
O	549	552	the
O	553	563	metastatic
O	564	571	setting
O	571	572	.

O	573	581	Patients
O	582	583	(
O	583	584	N
O	585	586	=
B-total-participants	587	590	137
O	590	591	)
B-eligibility	592	596	with
I-eligibility	597	601	HER2
I-eligibility	601	602	-
I-eligibility	602	610	positive
I-eligibility	611	614	MBC
I-eligibility	615	617	or
I-eligibility	618	627	recurrent
I-eligibility	628	635	locally
I-eligibility	636	644	advanced
I-eligibility	645	651	breast
I-eligibility	652	658	cancer
O	659	663	were
O	664	672	randomly
O	673	681	assigned
O	682	684	to
O	685	696	trastuzumab
O	697	701	plus
O	702	711	docetaxel
O	712	713	(
O	713	715	HT
O	715	716	;
O	717	718	n
O	719	720	=
B-control-participants	721	723	70
O	723	724	)
O	725	727	or
O	728	729	T
O	729	730	-
O	730	733	DM1
O	734	735	(
O	735	736	n
O	737	738	=
B-intervention-participants	739	741	67
O	741	742	)
O	743	745	as
O	746	751	first
O	751	752	-
O	752	756	line
O	757	766	treatment
O	767	772	until
O	773	780	disease
O	781	792	progression
O	793	795	or
O	796	808	unacceptable
O	809	817	toxicity
O	817	818	.

O	819	826	Primary
O	827	830	end
O	831	837	points
O	838	842	were
O	843	855	investigator
O	855	856	-
O	856	864	assessed
B-outcome-Measure	865	876	progression
I-outcome-Measure	876	877	-
I-outcome-Measure	877	881	free
I-outcome-Measure	882	890	survival
I-outcome-Measure	891	892	(
I-outcome-Measure	892	895	PFS
I-outcome-Measure	895	896	)
O	897	900	and
B-outcome-Measure	901	907	safety
O	907	908	.

O	909	912	Key
O	913	922	secondary
O	923	926	end
O	927	933	points
O	934	942	included
B-outcome-Measure	943	950	overall
I-outcome-Measure	951	959	survival
I-outcome-Measure	960	961	(
I-outcome-Measure	961	963	OS
I-outcome-Measure	963	964	)
O	964	965	,
B-outcome-Measure	966	975	objective
I-outcome-Measure	976	984	response
I-outcome-Measure	985	989	rate
I-outcome-Measure	990	991	(
I-outcome-Measure	991	994	ORR
I-outcome-Measure	994	995	)
O	995	996	,
B-outcome-Measure	997	1005	duration
I-outcome-Measure	1006	1008	of
I-outcome-Measure	1009	1018	objective
I-outcome-Measure	1019	1027	response
O	1027	1028	,
B-outcome-Measure	1029	1037	clinical
I-outcome-Measure	1038	1045	benefit
I-outcome-Measure	1046	1050	rate
O	1050	1051	,
O	1052	1055	and
B-outcome-Measure	1056	1063	quality
I-outcome-Measure	1064	1066	of
I-outcome-Measure	1067	1071	life
O	1071	1072	.

B-outcome	1073	1079	Median
I-outcome	1080	1083	PFS
O	1084	1087	was
B-cv-cont-median	1088	1089	9
I-cv-cont-median	1089	1090	.
I-cv-cont-median	1090	1091	2
I-cv-cont-median	1092	1098	months
O	1099	1103	with
O	1104	1106	HT
O	1107	1110	and
B-iv-cont-median	1111	1113	14
I-iv-cont-median	1113	1114	.
I-iv-cont-median	1114	1115	2
I-iv-cont-median	1116	1122	months
O	1123	1127	with
O	1128	1129	T
O	1129	1130	-
O	1130	1133	DM1
O	1134	1135	(
O	1135	1141	hazard
O	1142	1147	ratio
O	1147	1148	,
O	1149	1150	0
O	1150	1151	.
O	1151	1153	59
O	1153	1154	;
O	1155	1157	95
O	1157	1158	%
O	1159	1161	CI
O	1161	1162	,
O	1163	1164	0
O	1164	1165	.
O	1165	1167	36
O	1168	1170	to
O	1171	1172	0
O	1172	1173	.
O	1173	1175	97
O	1175	1176	)
O	1176	1177	;
B-outcome	1178	1184	median
I-outcome	1185	1191	follow
I-outcome	1191	1192	-
I-outcome	1192	1194	up
O	1195	1198	was
O	1199	1212	approximately
B-iv-cont-median	1213	1215	14
I-iv-cont-median	1216	1222	months
O	1223	1225	in
O	1226	1230	both
O	1231	1235	arms
O	1235	1236	.

B-outcome	1237	1240	ORR
O	1241	1244	was
B-cv-bin-percent	1245	1247	58
I-cv-bin-percent	1247	1248	.
I-cv-bin-percent	1248	1249	0
I-cv-bin-percent	1249	1250	%
O	1251	1252	(
O	1252	1254	95
O	1254	1255	%
O	1256	1258	CI
O	1258	1259	,
O	1260	1262	45
O	1262	1263	.
O	1263	1264	5
O	1264	1265	%
O	1266	1268	to
O	1269	1271	69
O	1271	1272	.
O	1272	1273	2
O	1273	1274	%
O	1274	1275	)
O	1276	1280	with
O	1281	1283	HT
O	1284	1287	and
B-iv-bin-percent	1288	1290	64
I-iv-bin-percent	1290	1291	.
I-iv-bin-percent	1291	1292	2
I-iv-bin-percent	1292	1293	%
O	1294	1295	(
O	1295	1297	95
O	1297	1298	%
O	1299	1301	CI
O	1301	1302	,
O	1303	1305	51
O	1305	1306	.
O	1306	1307	8
O	1307	1308	%
O	1309	1311	to
O	1312	1314	74
O	1314	1315	.
O	1315	1316	8
O	1316	1317	%
O	1317	1318	)
O	1319	1323	with
O	1324	1325	T
O	1325	1326	-
O	1326	1329	DM1
O	1329	1330	.

O	1331	1332	T
O	1332	1333	-
O	1333	1336	DM1
O	1337	1340	had
O	1341	1342	a
O	1343	1352	favorable
B-outcome	1353	1359	safety
I-outcome	1360	1367	profile
O	1368	1374	versus
O	1375	1377	HT
O	1377	1378	,
O	1379	1383	with
O	1384	1389	fewer
B-outcome	1390	1395	grade
I-outcome	1396	1397	â‰¥
I-outcome	1398	1399	3
I-outcome	1400	1407	adverse
I-outcome	1408	1414	events
O	1415	1416	(
O	1416	1419	AEs
O	1419	1420	;
B-iv-bin-percent	1421	1423	46
I-iv-bin-percent	1423	1424	.
I-iv-bin-percent	1424	1425	4
I-iv-bin-percent	1425	1426	%
O	1427	1428	v
B-cv-bin-percent	1429	1431	90
I-cv-bin-percent	1431	1432	.
I-cv-bin-percent	1432	1433	9
I-cv-bin-percent	1433	1434	%
O	1434	1435	)
O	1435	1436	,
O	1437	1440	AEs
O	1441	1448	leading
O	1449	1451	to
B-outcome	1452	1461	treatment
I-outcome	1462	1478	discontinuations
O	1479	1480	(
B-iv-bin-percent	1480	1481	7
I-iv-bin-percent	1481	1482	.
I-iv-bin-percent	1482	1483	2
I-iv-bin-percent	1483	1484	%
O	1485	1486	v
B-cv-bin-percent	1487	1489	34
I-cv-bin-percent	1489	1490	.
I-cv-bin-percent	1490	1491	8
I-cv-bin-percent	1491	1492	%
O	1492	1493	)
O	1493	1494	,
O	1495	1496	[
O	1496	1505	corrected
O	1505	1506	]
O	1507	1510	and
B-outcome	1511	1518	serious
I-outcome	1519	1522	AEs
O	1523	1524	(
B-iv-bin-percent	1524	1526	20
I-iv-bin-percent	1526	1527	.
I-iv-bin-percent	1527	1528	3
I-iv-bin-percent	1528	1529	%
O	1530	1531	v
B-cv-bin-percent	1532	1534	25
I-cv-bin-percent	1534	1535	.
I-cv-bin-percent	1535	1536	8
I-cv-bin-percent	1536	1537	%
O	1537	1538	)
O	1538	1539	.

O	1540	1551	Preliminary
B-outcome	1552	1554	OS
O	1555	1562	results
O	1563	1567	were
O	1568	1575	similar
O	1576	1583	between
O	1584	1593	treatment
O	1594	1598	arms
O	1598	1599	;
O	1600	1606	median
O	1607	1613	follow
O	1613	1614	-
O	1614	1616	up
O	1617	1620	was
O	1621	1634	approximately
B-iv-cont-median	1635	1637	23
I-iv-cont-median	1638	1644	months
O	1645	1647	in
O	1648	1652	both
O	1653	1657	arms
O	1657	1658	.

O	1659	1661	In
O	1662	1666	this
O	1667	1677	randomized
O	1678	1683	phase
O	1684	1686	II
O	1687	1692	study
O	1692	1693	,
O	1694	1699	first
O	1699	1700	-
O	1700	1704	line
O	1705	1714	treatment
O	1715	1719	with
O	1720	1721	T
O	1721	1722	-
O	1722	1725	DM1
O	1726	1729	for
O	1730	1738	patients
O	1739	1743	with
O	1744	1748	HER2
O	1748	1749	-
O	1749	1757	positive
O	1758	1761	MBC
O	1762	1770	provided
O	1771	1772	a
O	1773	1784	significant
O	1785	1796	improvement
O	1797	1799	in
O	1800	1803	PFS
O	1803	1804	,
O	1805	1809	with
O	1810	1811	a
O	1812	1821	favorable
O	1822	1828	safety
O	1829	1836	profile
O	1836	1837	,
O	1838	1844	versus
O	1845	1847	HT
O	1847	1848	.
